Collaborative Health Sciences Program
HSET Degraders as Paclitaxel Sensitizers
Awarded in
2025
Cancer is the second leading cause of death in Wisconsin. Paclitaxel is a standard treatment for several types of cancer, including breast cancer, but nearly half of patients do not respond to it. This project aims to improve outcomes for cancer patients by developing a new combination therapy that can make resistant tumors more responsive to paclitaxel without harming healthy non-cancerous cells. This work could lead to the identification of new therapies for other types of cancers as well.